Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L Van Gaal

Safety, Tolerability and Sustained Weight Loss Over 2 Years With the Once-Daily Human GLP-1 Analog, Liraglutide

International Journal of Obesity

English

The Use of Multi-Frequency Impedance to Determine Total Body Water and Extracellular Water in Obese and Lean Female Individuals

International Journal of Obesity

English

Related publications

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

English

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-Week, Double-Blind, Randomized, Controlled Trial

English

Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients With Type 2 Diabetes in Germany

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Internal Medicine

Pharmacology

2016

English

Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study

English

GLP-1 Analog Liraglutide-Induced Cardiac Dysfunction Due to Energetic Starvation in Heart Failure With Non-Diabetic Dilated Cardiomyopathy

Cardiovascular Diabetology

Internal Medicine

Cardiology

Endocrinology

Cardiovascular Medicine

Metabolism

Diabetes

2019

English

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation Through a Calcium and AMPK Dependent Mechanism

PLoS ONE

Multidisciplinary

2014

English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today

2014

English

Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes

British Journal of Diabetes

2016

English

Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L Van Gaal

Safety, Tolerability and Sustained Weight Loss Over 2 Years With the Once-Daily Human GLP-1 Analog, Liraglutide

The Use of Multi-Frequency Impedance to Determine Total Body Water and Extracellular Water in Obese and Lean Female Individuals

Related publications

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-Week, Double-Blind, Randomized, Controlled Trial

Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients With Type 2 Diabetes in Germany

Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study

GLP-1 Analog Liraglutide-Induced Cardiac Dysfunction Due to Energetic Starvation in Heart Failure With Non-Diabetic Dilated Cardiomyopathy

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation Through a Calcium and AMPK Dependent Mechanism

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes

Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial